These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31310365)

  • 1. An evaluation of different Cripto-1 antibodies and their variable results.
    Gudbergsson JM; Duroux M
    J Cell Biochem; 2020 Jan; 121(1):545-556. PubMed ID: 31310365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.
    Ishii H; Zahra MH; Takayanagi A; Seno M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cripto-1 localizes to dynamic and shed filopodia associated with cellular migration in glioblastoma cells.
    Gudbergsson JM; Duroux M
    Eur J Cell Biol; 2019 Dec; 98(5-8):151044. PubMed ID: 31543278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
    Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
    Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
    Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
    J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
    Sandomenico A; Ruvo M
    Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cripto monoclonal antibodies.
    Hu XF; Xing PX
    Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.
    Baldassarre G; Bianco C; Tortora G; Ruggiero A; Moasser M; Dmitrovsky E; Bianco AR; Ciardiello F
    Int J Cancer; 1996 May; 66(4):538-43. PubMed ID: 8635871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the embryonic gene Cripto-1 in cancer and beyond.
    Bianco C; Salomon DS
    Expert Opin Ther Pat; 2010 Dec; 20(12):1739-49. PubMed ID: 21073352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cripto as a target for cancer immunotherapy.
    Hu XF; Xing PX
    Expert Opin Ther Targets; 2005 Apr; 9(2):383-94. PubMed ID: 15934922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.
    Focà A; Sanguigno L; Focà G; Strizzi L; Iannitti R; Palumbo R; Hendrix MJ; Leonardi A; Ruvo M; Sandomenico A
    Int J Mol Sci; 2015 Sep; 16(9):21342-62. PubMed ID: 26370966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
    Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
    Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.
    Yoon HJ; Hong JS; Shin WJ; Lee YJ; Hong KO; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Nov; 47(11):1023-31. PubMed ID: 21824804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
    Zoni E; Chen L; Karkampouna S; Granchi Z; Verhoef EI; La Manna F; Kelber J; Pelger RCM; Henry MD; Snaar-Jagalska E; van Leenders GJLH; Beimers L; Kloen P; Gray PC; van der Pluijm G; Kruithof-de Julio M
    Oncogene; 2017 Aug; 36(33):4739-4749. PubMed ID: 28394345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants modulating CRIPTO serum levels identified by genome-wide association study in Cilento isolates.
    Ruggiero D; Nappo S; Nutile T; Sorice R; Talotta F; Giorgio E; Bellenguez C; Leutenegger AL; Liguori GL; Ciullo M
    PLoS Genet; 2015 Jan; 11(1):e1004976. PubMed ID: 25629528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.
    Foley SF; van Vlijmen HW; Boynton RE; Adkins HB; Cheung AE; Singh J; Sanicola M; Young CN; Wen D
    Eur J Biochem; 2003 Sep; 270(17):3610-8. PubMed ID: 12919325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development.
    Minchiotti G; Parisi S; Liguori G; Signore M; Lania G; Adamson ED; Lago CT; Persico MG
    Mech Dev; 2000 Feb; 90(2):133-42. PubMed ID: 10640699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of Cripto-1 protein in development and target therapy of breast cancer].
    Lei T; Guo XJ; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):66-8. PubMed ID: 20388407
    [No Abstract]   [Full Text] [Related]  

  • 19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis.
    Friess H; Yamanaka Y; Büchler M; Kobrin MS; Tahara E; Korc M
    Int J Cancer; 1994 Mar; 56(5):668-74. PubMed ID: 8314343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.